CD4+CD25+Foxp3+调节性T细胞与肺癌的临床分期及化疗关系的研究

Study the Relationship of Treg and the Clinical Stage and Chemotherapy of Lung Cancer

为了研究Treg与肺癌的临床分期及化疗的关系,分离52例初治肺癌患者化疗前后PBMC,以12例正常者为对照,荧光标记的单抗染色,流式细胞仪检测Treg占CD4+T细胞的比值。结果显示肺癌患者该比值高于对照组,III+IV期的高于I+II期。化疗疗效(SD+PD)高于PR。因此,肺癌患者Treg比例较正常人升高,且分期越高该比值增加越明显;疗效差的该比值高于化疗有效病例。推测Treg升高与肺癌的发生、发展有关。

To investigate the relations of Treg with clinical stages and chemotherapy efficacy of lung cancer. PBMCs isolated from the 52 cases lung cancer patients before and after chemotherapy were analyzed by flow cytometry, after beening stained by antibody , 12 normal volunteers were served as control. The proportion of Treg increased markedly in lung cancer patientsthan that in health adults . And it was also significantly higher in Ⅲ＋Ⅳ stagesthan that in Ⅰ＋Ⅱ. And the ratio in PR was significantly lower than that in （SD＋ PD）. The ratio of Treg is higher in peripheral blood of lung cancer patients than that in control, and the higher the stages, the more obvious increase of the ratio. The ratio of poor effect was significantly higher than that of effective chemotherapy, So Treg has close relation to development of lung cancer.